Actavis PLC is in talks to acquire Forest Laboratories, Inc. (NYSE:FRX) for $25 billion, compared to a market cap of about $19.3 billion, report Dana Mattioli, Jonathan D. Rockoff, and Dana Cimilluca for The Wall Street Journal. The deal could be officially announced as early as today, though the exact terms are not set and it seems there is still a chance that one of the sides will back out. Recent acquisitions by Actavis, Forest Labs Both pharmaceutical companies have been actively engaged in acquisitions recently. Actavis, which mostly deals with generic medications, bought Warner Chilcott in October 2013 in an…